文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

尽管存在严重的并发感染，仍用emapalumab 治疗难治性噬血细胞性淋巴组织细胞增生症。

Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

机构信息

Cancer and Blood Diseases Institute and.

Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

出版信息

Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858.

DOI:10.1182/bloodadvances.2018025858
PMID:30617216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6325304/
Abstract

Neutralization of IFN-γ with emapalumab can reverse severe, refractory hemophagocytic lymphohistiocytosis. Neutralizing IFN-γ did not impair control of multiple viral and other infections in a severely ill patient.

摘要

使用emapalumab 中和 IFN-γ 可逆转严重、难治性噬血细胞性淋巴组织细胞增生症。中和 IFN-γ 并未损害严重疾病患者对多种病毒和其他感染的控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70e1/6325304/cfa3e61a3a51/advances025858absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70e1/6325304/cfa3e61a3a51/advances025858absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70e1/6325304/cfa3e61a3a51/advances025858absf1.jpg

相似文献

[1]
Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

Blood Adv. 2019-1-8

[2]
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

N Engl J Med. 2020-5-7

[3]
Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL).

Front Immunol. 2020-12-2

[4]
Emapalumab: First Global Approval.

Drugs. 2019-1

[5]
Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.

Pediatr Blood Cancer. 2024-2

[6]
Emapalumab for the treatment of hemophagocytic lymphohistiocytosis.

Drugs Today (Barc). 2020-7

[7]
Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis.

Expert Rev Clin Pharmacol. 2021-5

[8]
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Blood. 2019-11-21

[9]
Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy.

J Clin Immunol. 2020-7

[10]
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.

Pediatr Blood Cancer. 2021-7

引用本文的文献

[1]
Novel strategies to manage CAR-T cell toxicity.

Nat Rev Drug Discov. 2025-5

[2]
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.

J Hematol Oncol. 2024-11-7

[3]
Emapalumab as a therapeutic intervention for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A case series.

Medicine (Baltimore). 2024-9-27

[4]
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study.

Arthritis Rheumatol. 2025-2

[5]
Anti-Interferon-γ Therapy for Cytokine Storm Syndromes.

Adv Exp Med Biol. 2024

[6]
IL-1 Family Blockade in Cytokine Storm Syndromes.

Adv Exp Med Biol. 2024

[7]
The History of Macrophage Activation Syndrome in Autoimmune Diseases.

Adv Exp Med Biol. 2024

[8]
Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update.

Mol Biotechnol. 2025-6

[9]
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.

Exp Mol Med. 2024-3

[10]
Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade.

J Clin Immunol. 2024-2-24

本文引用的文献

[1]
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.

Blood. 2017-12-21

[2]
Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome.

J Allergy Clin Immunol. 2017-8-12

[3]
Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience.

Pediatr Blood Cancer. 2016-10-27

[4]
Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis.

Transl Res. 2017-2

[5]
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Ann Rheum Dis. 2016-6-13

[6]
Pathogenesis of Hemophagocytic Lymphohistiocytosis.

Hematol Oncol Clin North Am. 2015-10

[7]
Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.

Rheumatology (Oxford). 2015-3-12

[8]
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.

Pediatr Blood Cancer. 2012-4-22

[9]
Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children.

J Pediatr. 2012-1-9

[10]
Expression of type I interferon by splenic macrophages suppresses adaptive immunity during sepsis.

EMBO J. 2011-10-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索